• 1. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 2. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 3. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 4. Emerging investigator series: kinetics of diopside reactivity for carbon mineralization in mafic–ultramafic rocks
  BrianaAguila,LandonHardee,H.ToddSchaef,SiavashZare,MohammadJavadAbdolhosseiniQomi,JarrodV.Crum,JadeE.HollimanJr.,ElenaTajueloRodriguez,LawrenceM.Anovitz,KevinM.Rosso,QuinR.S.Miller
• 5. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291

Recent Advances in the Application of 1217977-71-3 and a-Me-Asp(OtBu)-OH in Chemical Biology and Pharmaceutical Research

The chemical compound with the CAS number 1217977-71-3 and the product a-Me-Asp(OtBu)-OH have garnered significant attention in recent years due to their potential applications in chemical biology and pharmaceutical research. These compounds are particularly relevant in the synthesis of modified peptides and peptidomimetics, which play a crucial role in drug discovery and development. This research brief aims to summarize the latest findings related to these compounds, focusing on their synthesis, biological activity, and potential therapeutic applications.

Recent studies have highlighted the importance of 1217977-71-3 as a key intermediate in the synthesis of complex organic molecules. Its unique chemical properties make it an ideal candidate for the development of novel pharmaceuticals, particularly in the field of oncology and infectious diseases. Meanwhile, a-Me-Asp(OtBu)-OH, a protected form of aspartic acid, has been extensively used in peptide synthesis to improve stability and bioavailability. Researchers have explored its incorporation into peptide chains to enhance their pharmacological properties.

One of the most notable advancements involves the use of 1217977-71-3 in the development of kinase inhibitors. Kinases are critical targets in cancer therapy, and the ability to modulate their activity with high specificity is a major focus of current research. Studies have demonstrated that derivatives of 1217977-71-3 exhibit potent inhibitory effects on specific kinase pathways, offering promising leads for the treatment of various cancers. Additionally, a-Me-Asp(OtBu)-OH has been employed in the design of peptide-based therapeutics, where its incorporation has been shown to improve metabolic stability and target binding affinity.

In terms of synthetic methodologies, recent publications have described innovative approaches to the preparation of 1217977-71-3 and a-Me-Asp(OtBu)-OH. These methods emphasize efficiency, scalability, and environmental sustainability, addressing some of the key challenges in large-scale pharmaceutical production. For instance, green chemistry techniques have been applied to reduce the use of hazardous reagents and solvents, aligning with the industry's growing emphasis on sustainable practices.

The biological evaluation of these compounds has also yielded insightful results. Preclinical studies have investigated the pharmacokinetics and pharmacodynamics of 1217977-71-3 derivatives, revealing favorable profiles in terms of absorption, distribution, metabolism, and excretion (ADME). Similarly, a-Me-Asp(OtBu)-OH-containing peptides have demonstrated enhanced stability in biological matrices, making them suitable candidates for further development. These findings underscore the potential of these compounds to advance the field of medicinal chemistry.

Looking ahead, the integration of 1217977-71-3 and a-Me-Asp(OtBu)-OH into drug discovery pipelines holds great promise. Researchers are exploring their utility in combination therapies, where their synergistic effects could lead to improved therapeutic outcomes. Furthermore, advancements in computational modeling and artificial intelligence are expected to accelerate the identification of optimal derivatives and formulations, paving the way for next-generation pharmaceuticals.

In conclusion, the ongoing research on 1217977-71-3 and a-Me-Asp(OtBu)-OH highlights their significant potential in chemical biology and pharmaceutical applications. Their roles in peptide synthesis, kinase inhibition, and drug development underscore the importance of continued investigation. As the field progresses, these compounds are likely to play an increasingly vital role in addressing unmet medical needs and advancing therapeutic innovation.

• 147092-17-9(L-Isovaline, 3-methyl-, 1,1-dimethylethyl ester)
• 204125-96-2(Aspartic acid, 3-(2-methylpropyl)-, 1-(1,1-dimethylethyl) ester, (3R)-)
• 3057-74-7(L-Aspartic acid 4-tert-butyl ester)
• 1214851-34-9(2-Amino-4-(tert-butoxy)-3,3-dimethyl-4-oxobutanoic acid)
• 467221-68-7(L-Isovaline, 3-methyl-, 1,1-dimethylethyl ester, hydrochloride)
• 64960-75-4(H-D-Asp(OtBu)-OH)
• 700338-19-8(PROPAN-2-YL 2-AMINO-2-METHYLBUTANOATE)
• 84310-97-4(tert-butyl 2-amino-2-ethylbutanoate)
• 1231709-25-3(a-Me-D-Asp(OtBu)-OH)
• 482631-89-0(L-Aspartic acid, 3-methyl-, 4-(1,1-dimethylethyl) ester, (3S)-)